Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine-Reference-Cited by-同舟云学术

Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine

Published:2009-03-01 Issue:5 Volume:115 Page:1041-1048
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Garcia Mar,Romaguera Jorge E.,Inamdar Kedar V.,Rassidakis George Z.,Medeiros L. Jeffrey

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference18 articles.

1. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways;Fernandez;J Clin Oncol.,2005

2. Treatment of mantle cell lymphoma: current approach and future directions;Brody;Crit Rev Oncol Hematol.,2006

3. Current management of mantle cell lymphoma;Weigert;Drugs.,2007

4. Mantle cell lymphoma: advances in biology and therapy;Smith;Curr Opin Hematol.,2008

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review;Critical Reviews in Oncology/Hematology;2021-02

2. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma;Annals of Nuclear Medicine;2019-03-30

3. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma;Cancer;2018-05-03

4. Mantle cell lymphoma presenting as bilateral adrenal huge masses;BMJ Case Reports;2018-04-17

5. Pathology of Non-Hodgkin and Hodgkin Lymphomas;Neoplastic Diseases of the Blood;2017-09-22